To test our hypothesis that initiating therapy with a combination of agents known to improve insulin secretion and insulin sensitivity in subjects with new-onset diabetes would produce greater , more durable reduction in glycated haemoglobin ( HbA1c ) levels , while avoiding hypoglycaemia and weight gain , compared with sequential addition of agents that lower plasma glucose but do not correct established pathophysiological abnormalities .